were used in the study: OLP (Tokyo Chemical Industry, Zwijndrecht,
Belgium); Gantrez S-97 (a copolymer of methyl vinyl ether and maleic
acid), PVP (58 and 360 kDa, sold under the product brand names Plasdone
K-29/32 and K-90), and β-CD, HP-β-CD, γ-CD, and
HP-γ-CD (sold under the product brand names of Cavamax W7, Cavitron
W7, Cavamax W8, and Cavasol W8, respectively, Ashland, Vale Industrial
Estate, Kidderminster, U.K.); sorbitol, poly(ethylene glycol) (PEG,
MW 3400 and 10,000 Da), poly(vinyl alcohol) (PVA, MW 85–124
kDa, 87–89% hydrolyzed), PVA (MW 9–10 kDa, 80% hydrolyzed),
and
(TPGS, Sigma-Aldrich, Steinheim, Germany); crospovidone (CPV, sold
under the product brand name Kollidon CL-SF, O-BASF, Ludwigshafen,
Germany); anhydrous citric acid, anhydrous glucose, and anhydrous
sodium carbonate (Na2CO3) (BDH Laboratory Supplies,
Poole, Dorset, England); Parafilm M laboratory film (Bemis Company
Inc., Soignies, Belgium); siliconized release liner (Rexam Release
B.V., Apeldoom, The Netherlands); pluronic F-108 (VWR Chemicals LLC,
Solon, OH); poly(lactic acid) (PLA) (Ultimaker, Geldermalsen, Netherlands);
Kinesiology Sports tape (95% cotton, 5% spandex; 5 × 500 cm;
Proworks Corporation, Corvallis, OR); and microfoam surgical tape
and Tegaderm dressing (3 M, Bracknell, Berkshire, U.K.).